• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

    2/14/22 10:39:32 AM ET
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGND alert in real time by email
    SC 13G/A 1 d305355dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Ligand Pharmaceuticals Inc.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    53220K504

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

      ☐

    Rule 13d-1(c)

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 53220K504

     

     

      1.    

      Names of Reporting Persons

     

      Macquarie Group Limited

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Sydney, New South Wales Australia

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

    0

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    624,969 deemed beneficially owned due to reporting person’s ownership of Macquarie Management Holdings Inc., Macquarie Investment Management Business Trust and Macquarie Investment Management Global Limited whose individual holdings are shown on the following forms.

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      3.74%

    12.  

      Type of Reporting Person (See Instructions)

     

      HC

     

    Page 2 of 12


    CUSIP No. 53220K504

     

     

      1.    

      Names of Reporting Persons

     

      Macquarie Management Holdings Inc

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      State of Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      618,559

       6.  

      Shared Voting Power

     

    0

       7.  

      Sole Dispositive Power

     

      618,559

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

    624,720 deemed beneficially owned due to reporting person’s ownership of Macquarie Investment Management Business Trust

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☒

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      3.74%

    12.  

      Type of Reporting Person (See Instructions)

     

      HC

     

    Page 3 of 12


    CUSIP No. 53220K504

     

     

      1.    

      Names of Reporting Persons

     

      Macquarie Investment Management Business Trust

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      State of Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      618,559

       6.  

      Shared Voting Power

     

    0

       7.  

      Sole Dispositive Power

     

      618,559

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      624,720

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☒

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      3.74%

    12.  

      Type of Reporting Person (See Instructions)

     

      IA

     

    Page 4 of 12


    CUSIP No. 53220K504

     

     

      1.    

      Names of Reporting Persons

     

      Macquarie Investment Management Global Limited

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Sydney, New South Wales, Australia

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      249

       6.  

      Shared Voting Power

     

    0

       7.  

      Sole Dispositive Power

     

      249

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      249

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.00%

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

     

     

    Page 5 of 12


    Item 1.
       (a)  

    Name of Issuer

    Ligand Pharmaceuticals Inc

       (b)  

    Address of Issuer’s Principal Executive Offices

    3911 Sorrento Valley Blvd Ste 110, San Diego, CA 92121-1402

    Item 2.    
       (a)  

    Name of Person Filing

    This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Management Holdings Inc, Macquarie Investment Management Business Trust and Macquarie Investment Management Global Limited

       (b)  

    Address of Principal Business Office or, if none, Residence

    The principal business address of Macquarie Group Limited and Macquarie Investment Management Global Limited is 50 Martin Place Sydney, New South Wales, Australia. The principal business address of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust is 2005 Market Street, Philadelphia, PA 19103.

       (c)  

    Citizenship

    Macquarie Group Limited and Macquarie Investment Management Global Limited—Sydney, New South Wales, Australia Corporation

    Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust – incorporated or formed under the laws of the State of Delaware.

       (d)  

    Title of Class of Securities

    Common Stock

       (e)  

    CUSIP Number

    53220K504

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       (a)   ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)   ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)   ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)   ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)   ☒   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)   ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)   ☒   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       (h)   ☐   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)   ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)   ☐   A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
       (k)   ☐   Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________

     

    Page 6 of 12


    Item 4.    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       (a)   

    Amount beneficially owned:

    See responses on the cover page hereto.

       (b)   

    Percent of class:

    See responses on the cover page hereto.

       (c)   

    Number of shares as to which the person has:

     

          (i)   

    Sole power to vote or to direct the vote

    See responses on the cover page hereto.

          (ii)   

    Shared power to vote or to direct the vote

    0

          (iii)   

    Sole power to dispose or to direct the disposition of

    See responses on the cover page hereto.

          (iv)   

    Shared power to dispose or to direct the disposition of

    0

    Item 5.    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
    See Exhibit A.
    Item 8.    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.    Notice of Dissolution of Group
    Not applicable.

     

    Page 7 of 12


    Item 10.

      

    Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Group Limited    February 11, 2022
       Date
    /s/ Paul Peduto    /s/ Charles Glorioso
    Signature    Signature
          

    Paul Peduto

    Associate Director

      

    Charles Glorioso

    Division Director

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Management Holdings, Inc.    February 11, 2022
       Date
    /s/ Brian L. Murray   
    Signature   
        

    Brian L. Murray

    Chief Compliance Officer

      

     

    Macquarie Investment Management Business Trust    February 11, 2022
       Date
    /s/ Brian L. Murray   
    Signature   
        

    Brian L. Murray

    Chief Compliance Officer

      

     

    Page 8 of 12


    EXHIBIT A

    AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS

    AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”).

    WHEREAS, the parties hereto may be deemed to be the direct or indirect beneficial owners of the same equity securities for the purpose of the reporting requirements of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and

    WHEREAS, the regulations promulgated under Section 13(d) of the Exchange Act permit the joining of such beneficial owners in the filing of a single Joint Acquisition Statement reporting such ownership to the Securities and Exchange Commission.

    NOW, THEREFORE, in consideration of the mutual covenants herein contained, and each of the parties hereto intending to be legally bound, it is agreed as follows:

    1. In the event that any two or more parties shall be deemed to be the direct or indirect beneficial owners of the same equity security required to be reported to the Securities and Exchange Commission such parties may join together in the filing of a Joint Acquisition Statement with respect to that security. Additional persons who may after the date hereof be deemed to be the direct or indirect beneficial owners of the same equity security as a party hereto and required to be reported to the Securities and Exchange Commission (a “New Party”) may be added as a party this agreement by signing a counterpart hereof. An amendment to this agreement is deemed effective upon the signature of such new party and the amendment of the applicable Annex which may be affixed to this agreement as amended. Each party hereto agrees that this agreement, as it may be amended from time to time as provided herein, is a valid and binding agreement of each such party.

    2. With respect to each Joint Acquisition Statement in which a party joins, each party acknowledges that (a) it will be eligible under applicable regulations of the Securities and Exchange Commission to join in the filing and (b) it will be responsible for the timely filing of such statement and any amendments thereto and the completeness and accuracy of the information concerning such party; but each such party shall not be responsible for the completeness and accuracy of the information concerning the other parties making the filing, unless such party knows or has reason to believe that such information with respect to such other parties is inaccurate.

    3. The parties consent to the inclusion of a copy of this agreement as an exhibit to any Joint Acquisition Statement filed on behalf of any of them.

     

    Page 9 of 12


    IN WITNESS WHEREOF, the parties hereto have executed this agreement by their duly authorized officers as of the date set forth above.

    DELAWARE FUNDS® BY MACQUARIE (listed on Annex A hereto)

    ATTEST BY:

     

    /s/ Brian L. Murray    /s/ David Connor
    Signature    Signature
          

    Brian L. Murray

    Chief Compliance Officer

      

    David Connor

    General Counsel

    MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST

     

    /s/ Brian L. Murray    /s/ David Connor
    Signature    Signature
          

    Brian L. Murray

    Chief Compliance Officer

      

    David Connor

    General Counsel

    MACQUARIE MANAGEMENT HOLDINGS, INC.

     

    /s/ Brian L. Murray    /s/ David Connor
    Signature    Signature
          

    Brian L. Murray

    Chief Compliance Officer

      

    David Connor

    General Counsel

    THE MACQUARIE PARTIES (LISTED ON ANNEX B HERETO)

    ATTEST BY:

     

    /s/ Paul Peduto    /s/ Charles Glorioso
    Signature    Signature
          

    Paul Peduto

    Associate Director

      

    Charles Glorioso

    Division Director

     

    Page 10 of 12


    Annex A— Delaware FundsSM by Macquarie

    DELAWARE GROUP EQUITY FUNDS I

    DELAWARE GROUP EQUITY FUNDS II

    DELAWARE GROUP EQUITY FUNDS IV

    DELAWARE GROUP EQUITY FUNDS V

    DELAWARE GROUP INCOME FUNDS

    DELAWARE GROUP LIMITED-TERM GOVERNMENT FUNDS

    DELAWARE GROUP CASH RESERVE

    DELAWARE GROUP GOVERNMENT FUND

    DELAWARE GROUP STATE TAX-FREE INCOME TRUST

    DELAWARE GROUP TAX-FREE FUND

    DELAWARE GROUP GLOBAL & INTERNATIONAL FUNDS

    DELAWARE GROUP ADVISER FUNDS

    DELAWARE VIP TRUST

    DELAWARE POOLED TRUST

    DELAWARE GROUP FOUNDATION FUNDS

    DELAWARE INVESTMENTS DIVIDEND AND INCOME FUND, INC.

    DELAWARE ENHANCED GLOBAL DIVIDEND AND INCOME FUND

    INVESTED PORTFOLIOS

    IVY HIGH INCOME OPPORTUNITIES FUND

    IVY FUNDS

    IVY VARIABLE INSURANCE PORTFOLIOSSM

    VOYAGEUR INSURED FUNDS

    VOYAGEUR INTERMEDIATE TAX FREE FUNDS

    VOYAGEUR MUTUAL FUNDS

    VOYAGEUR MUTUAL FUNDS II

    VOYAGEUR MUTUAL FUNDS III

    VOYAGEUR TAX FREE FUNDS

    DELAWARE INVESTMENTS COLORADO MUNICIPAL INCOME FUND, INC.

    DELAWARE INVESTMENTS NATIONAL MUNICIPAL INCOME FUND

    DELAWARE INVESTMENTS MINNESOTA MUNICIPAL INCOME FUND II, INC.

     

    Page 11 of 12


    Annex B — the Macquarie Parties

    Macquarie Group Limited

    Macquarie Affiliated Managers (USA) Inc.

    Macquarie Affiliated Managers Holdings (USA) Inc.

    Macquarie Americas Holdings Pty Ltd.

    Macquarie B.H. Pty Limited

    Macquarie FG Holdings Inc.

    Macquarie Funding Holdings LLC

    Macquarie Investment Management Europe Limited

    EXHIBIT B

    Powers of Attorney for Macquarie Group Limited and incorporated by reference to 13G filings made by Macquarie Group Limited and on May 25, 2021.

     

    Page 12 of 12

    Get the next $LGND alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LGND

    DatePrice TargetRatingAnalyst
    4/10/2025$143.00Buy
    Stifel
    10/3/2024$135.00Outperform
    Oppenheimer
    7/30/2024$130.00Outperform
    RBC Capital Mkts
    2/22/2022$180.00 → $130.00Buy
    Benchmark
    2/18/2022$185.00 → $165.00Overweight
    Barclays
    9/22/2021$174.00 → $180.00Overweight
    Barclays
    7/30/2021$200.00 → $190.00Buy
    Roth Capital
    More analyst ratings

    $LGND
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Davis Todd C bought $1,000,456 worth of shares (9,510 units at $105.20), increasing direct ownership by 6% to 161,234 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      5/13/25 8:05:16 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Espinoza Octavio bought $156,090 worth of shares (1,500 units at $104.06), increasing direct ownership by 6% to 27,932 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      5/13/25 8:04:05 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Davis Todd C bought $243,480 worth of shares (2,500 units at $97.39), increasing direct ownership by 2% to 123,010 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      8/9/24 5:52:17 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kozarich John W sold $116,750 worth of shares (934 units at $125.00), decreasing direct ownership by 2% to 46,456 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      7/11/25 6:17:22 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CLO & Secretary Reardon Andrew acquired $21,221 worth of shares (233 units at $91.08), increasing direct ownership by 0.73% to 32,136 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      7/2/25 7:32:33 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Espinoza Octavio acquired $20,401 worth of shares (224 units at $91.08), increasing direct ownership by 0.76% to 29,852 units (SEC Form 4)

      4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)

      7/2/25 7:32:09 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

      JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum. The Company has earned a $5 million milestone payment from Pelthos following the commercial launch of ZELSUVMI. "Molluscum impacts millions of people in the U.S., particularly children. We are thrilled to see that ZELSUVMI is now commercially available as it addresses a significant unmet need for these patients as the first at-home treatment for this highly contagious viral ski

      7/10/25 8:00:00 AM ET
      $LGND
      $PTHS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

      The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

      7/2/25 7:00:00 AM ET
      $CHRO
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

      Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI Pelthos will commence trading on the NYSE American exchange under the new ticker symbol "PTHS" on July 2, 2025 JUPITER, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced the completion of its previously announced merger between the company's wholly owned subsidiary, LNHC, Inc., and CHRO Merger Sub Inc., a wholly owned subsidiary of Channel Therapeutics Corporation ("Channe

      7/2/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Ligand Pharma with a new price target

      Stifel initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $143.00

      4/10/25 12:42:08 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Ligand Pharma with a new price target

      Oppenheimer initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $135.00

      10/3/24 7:34:05 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ligand Pharma with a new price target

      RBC Capital Mkts initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $130.00

      7/30/24 6:24:41 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    SEC Filings

    See more
    • Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      7/2/25 7:10:18 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)

      6/9/25 4:03:39 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ligand Pharmaceuticals Incorporated

      SCHEDULE 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      5/14/25 12:31:11 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated

      SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      11/1/24 4:07:52 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ligand Pharmaceuticals Incorporated

      SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      2/14/24 6:26:25 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ligand Pharmaceuticals Incorporated (Amendment)

      SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)

      2/13/24 5:08:05 PM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports First Quarter 2025 Financial Results

      First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share of $6.00-$6.251 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2025, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8

      5/8/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

      JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update. Conference Call and Webcast InformationDate: Thursday, May 8, 2025   Time: 8:30 AM Eastern Time   Conference Call: (800) 715-9871 (U.S. & Canada)  (646) 307-1963 (International)  Conference ID 3661098   Webcast: Live and replay webcasts of the call are available here.    About Ligand PharmaceuticalsLiga

      4/24/25 7:00:00 AM ET
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

      Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic skin diseases Top-line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs), on track for the first quarter of 2026 Top-line results from TOIVA, a Phase 2 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of

      3/31/25 7:30:00 AM ET
      $LGND
      $PVLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGND
    Leadership Updates

    Live Leadership Updates

    See more
    • Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

      The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

      7/2/25 7:00:00 AM ET
      $CHRO
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

      WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

      10/17/24 7:30:00 AM ET
      $LFCR
      $LGND
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OmniAb Announces Completion of Spin-Off and Business Combination

      Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

      11/1/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care